Table 1 Clinical characteristics of patients treated with doublet vs. triplet regimens.
Characteristics | Doublet (N = 60) N (%), Median [Range] | Triplet (N = 27) N (%), Median [Range] | P |
|---|---|---|---|
Median age, years | 71 [51–83] | 69 [40–85] | 0.17 |
Age ≥75 years old | 22 (37) | 7 (26) | 0.32 |
Male gender | 30 (50) | 11 (41) | 0.42 |
Type of AML | |||
De novo | 43 (71) | 20 (74) | 0.97 |
Secondary AML | 7 (12) | 3 (11) | |
Therapy related | 10 (17) | 4 (15) | |
WBC, x109/L | 5.3 [0.3–164] | 4.2 [1–201] | 0.62 |
Hemoglobin, g/dl | 9.2 [7–13] | 9.0 [6–12] | 0.12 |
Platelets, x109/L | 27 [3–326] | 53 [9–116] | 0.01 |
Creatinine | 0.9 [0.5–4.5] | 0.9 [0.5–2.2] | 0.9 |
Total Bilirubin | 0.6 [0.2–7.9] | 0.5 [0.2–1.6] | 0.29 |
Peripheral blood blasts, % | 26 [0–98] | 19 [0–89] | 0.7 |
Bone marrow blasts, % | 70 [22–97] | 60 [22–85] | 0.39 |
Cytogenetics | |||
Diploid | 37 (62) | 13 (48) | 0.57 |
Complex/−5/−7 | 6 (10) | 5 (19) | |
Other | 12 (20) | 7 (26) | |
Insufficient Metaphase | 5 (8) | 2 (7) | |
FLT3 Mutation | |||
ITD (only) | 53 (88) | 21 (78) | <0.01 |
D835 (only) | 0 (0) | 5 (18) | |
ITD/D835 (both) | 7 (12) | 1 (4) | |
Baseline Allelic Ratio | |||
ITD | 0.71 [0.06–4.1] | 0.41 [0–3.34] | <0.01 |
D835 | 0 [0-0.41] | 0 [0-0.46] | 0.17 |
Other Mutations | |||
NPM1 | 30/58 (52) | 12/27 (44) | 0.53 |
DNMT3A | 23/57 (40) | 11/26 (42) | 0.86 |
RAS | 8/56 (14) | 4/27 (15) | 0.94 |
IDH2 | 8/57 (14) | 5/27 (18) | 0.59 |
RUNX1 | 4/39 (10) | 3/27 (11) | 0.91 |
CEBPA | 5/53 (9) | 1/27 (4) | 0.35 |
ASXL1 | 3/39 (8) | 2/27 (7) | 0.96 |
IDH1 | 4/57 (7) | 3/27 (11) | 0.52 |
TP53 | 4/52 (7) | 1 /27 (4) | 0.49 |
